Clinical Trials in Houston

Showing 3621-3640 of 12,700 trials

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

NCT03894618

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

Squamous Cell Carcinoma of the Head and NeckMelanomaNon Small Cell Lung Cancer+10 more

Shattuck Labs, Inc.49 participantsStarted Mar 2019

Nashville, Tennessee, United States • Houston, Texas, United States • Leuven, Belgium +2 more locations

COMPLETEDPhase 2< 1 mile

XEN1101 for Major Depressive Disorder

NCT04827901

This project is designed to examine the neuronal KCNQ2/3 potassium (K+) channel subtype as a novel treatment target for mood disorders through the administration of the KCNQ-selective channel opener XEN1101 (Xenon Pharmaceuticals).

Major Depressive Disorder

James Murrough44 participantsStarted Oct 2021

New York, New York, United States • Houston, Texas, United States

COMPLETEDPhase 3< 1 mile

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

NCT04450693

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Diabetic Foot InfectionNon-healing WoundNon-healing Diabetic Foot Ulcer

BioTissue Holdings, Inc106 participantsStarted Nov 2020

Guntersville, Alabama, United States • Tucson, Arizona, United States • Los Angeles, California, United States +13 more locations

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

XEN1101 for Major Depressive Disorder

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Find Trials by Condition in Houston

Effect of Sex on Orthostatic Intolerance and Cardiovascular Response During Lunar Descent and Ascent

Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery

Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure

Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects

Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.)

BATwire Implant Kit

Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment